David D. Thiel, MD

David D. Thiel, MD, chair, discusses the measures that are being taken to protect patients and providers from the coronavirus disease 2019 (COVID-19).

David D. Thiel, MD, chair, Department of Urology, Mayo Clinic, discusses the advancements in surgical techniques for renal cell carcinoma.

David D. Thiel, MD, chair, Department of Urology, Mayo Clinic, discusses resectability in metastatic renal cell carcinoma (mRCC).

David D. Thiel, MD, chair, Department of Urology, Mayo Clinic, discusses the phase III randomized CARMENA trial, which examined cytoreductive nephrectomy plus sunitinib versus sunitinib alone in patients with metastatic renal cell carcinoma.